Clinical trial NCT03096756: A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study Designed to Compare the Safety and Pharmacokinetics of Orally Administered Superoxide Dismutase Mimetic GC4702 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 (Part 1), With Assessment of Food Effect (Part 2), in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteer
Keywords: Oral Formulation
Food Effect
Superoxide Dismutase
Single Ascending Dose
GC4702
Bioavailability
Pharmacokinetics
Active Comparator
Lead sponsor: Galera Therapeutics, Inc.
Sponsor class: INDUSTRY
Collaborators: name: INC Research Australia Pty Ltd
name: Nucleous Network
First posted: 2017-03-30
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: SUPPORTIVE_CARE

Brief summary: A Phase 1 study will test the safety, tolerability and pharmacokinetics of a single dose of GC4702 when given as an oral tablet. This study will compare capsules containing a dry powder or gel suspension of GC4702 when given orally to a similar drug called GC4419 which will be given as an intravenous infusion. This study will also assess the effect of food on the GC4702 effects.

Detailed description: The study will be conducted in two parts: Part 1, the main study, will be a double-blind, randomized, placebo-controlled, single-ascending dose assessment of GC4702. Part 2, which will be conducted only after Part 1 and contingent upon results from Part 1, will include a food-effect cohort using a randomized design of fed/fasted conditions.

Consenting subjects will undergo screening procedures within 28 days of the start of dosing. Pharmacokinetics (PK) (parent drug and major metabolites) will be assessed in plasma and urine from all subjects.

Part 1: GC4702 or matched placebo will be administered once by mouth for a single dose. Subjects in Cohort 3 will receive a dose of (dry powder formulation) oral GC4702 48 hours after a single dose of IV GC4419 administered over 60 minutes, and a dose of (lipid suspension formulation) GC4702 one week later. Subjects in Cohorts 4 will receive a single dose of (lipid suspension formulation) oral GC4702 48 hours after a single dose of IV GC4419 administered over 60 minutes. The first 8 Subjects in Cohort 4 are dosed as required by GTO-001 Protocol Amendment 1. Upon approval of GTO-001 Protocol Amendment 2, the first 8 previously dosed Subjects (fasted with water only) are considered dosing arm 4a for the analysis, and this and subsequent cohorts become eligible for expansion to study to other dosing conditions. Cohort 4 and up will receive a single dose of IV GC4419 on Day 1 administered over 60 minutes, followed by a single dose of (lipid suspension formulation) oral GC4702 48 hours after IV dosing, under varying and distinct GC4702 dosing conditions per dose level. At discretion of Medical Monitor and upon agreement by the Principal Investigator based on available data, up to 4 arms may be evaluated, where GC4702 doses are fixed within the cohort, but oral intake conditions are modified as described below:

1. with 240 mL (8 fluid ounces) of tap water only
2. with 240 mL (8 fluid ounces) of tap water following a high calorie/high fat meal. Subjects assigned to the fed condition will receive a standard meal per U.S. FDA guidelines consisting of high calorie/high fat meal prior to dosing consisting of total calories of 800-1000 of which 150, 250 and 500-600 calories are from protein, carbohydrate and fat, respectively. For the fed condition, GC4702 will be administered following an overnight fast of at least 10 hours. Subjects will start the standard meal 30 minutes prior to administration of GC4702, and will be instructed to eat the meal in 30 minutes or less; however, the GC4702 will be administered 30 minutes after the start of the meal, with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after GC4702 administration. Subjects will receive standardized meals scheduled at the same time in each period of the study.
3. with 240 mL (8 fluid ounces) of orange juice only
4. with 240 mL (8 fluid ounces) of tap water, immediately followed by a single unit adult dose of the over-the-counter antacid Rennie® only Subjects will be assigned to available arms (i.e., not all arms may be tested at every cohort), and dosing arms may be evaluated concurrently, or in sequence, both considerations determined by the Medical Monitor and Principal Investigator as warranted by available data and resources.

Two forms of the oral GC4702 drug product will be tested; both formulations will be enteric-coated Capsugel Vcap Plus hard gel capsule containing (1) a dry powder formulation or (2) lipid suspension formulation.

It is anticipated that a total of 6-7 dose cohorts will be tested, including the first two dose cohorts receiving only a single oral dose of escalating doses of the encapsulated dry powder GC4702 formulation, the third cohort receiving a single oral dose of each of oral GC4702 formulation sequentially after a single IV dose of GC4419, and 3-4 subsequent cohorts receiving a single oral dose of escalating doses of the oral encapsulated lipid suspension GC4702 formulation after a single IV dose of GC4419. Depending on safety and PK results, additional cohorts may be added with either drug product preparation. See below for an overview of study design.

The first two cohorts of subjects will receive only the encapsulated dry powder formulation, to assess acute safety and oral absorption of GC4702. Six subjects will be enrolled in each of the first two cohorts, randomized 4:2 to active GC4702 or matched placebo. After each of these two cohorts, safety data will be reviewed by the internal Galera Therapeutics, Inc. (Galera) study team before proceeding to the next cohort.

The third cohort of subjects will receive both oral formulations of GC4702, sequentially, after an initial single dose of IV GC4419, to permit intra-subject assessment of the bioavailability of both formulations of GC4702. Pending initial safety and PK results in this cohort, subsequent single dose escalation is anticipated in serial cohorts receiving only the encapsulated lipid suspension formulation of GC4702 by a single dose, after an initial single dose of IV GC4419.

For cohort 3 and 4 (Amendment 1), 8 subjects per cohort will be enrolled, randomized 6:2 to active GC4702 or matched placebo.

For expansion Cohort 4 (Amendment 2), 5 and up, 8 subjects per dosing arm will be enrolled, randomized 6:2 to active or matched placebo. Assignment of Subjects to open dosing arms is at the discretion of the investigational site, which considers Subject availability, the number of dosing arms tests (1 - 4 arms per cohort), and the sequence in which each arm is evaluated with the cohort. Subject crossover to other arms is prohibited at any time, once GC4702 has been administered.

All subjects enrolled in these cohorts will first receive IV GC4419. After each of these cohorts, safety and PK data will be reviewed by the internal Galera study team before proceeding to the next cohort. Depending on the inter-subject variability in oral bioavailability, additional subjects may be added to one or more dosing cohorts.

Sentinel cohorts will be enrolled for Cohorts 1 and 3 and will be observed for 24 hours after each dose of GC4702, with safety data reviewed by the treating investigator, before additional subjects receive the scheduled dose of GC4702 in the relevant cohort. Subjects in the single-ascending dose portion of the study will also undergo electrocardiogram (ECG) monitoring at selected PK time points, to include the estimated Tmax, (anticipated to be 2-4 hours after a dose of GC4702), to assess the relationship between drug exposure to GC4419/GC4702 and effects on the QT interval.

Part 2: After completion of the single-ascending dose portion of the study, a separate cohort of subjects will receive a single dose of GC4702 (at a dose no higher than previously found to have an acceptable safety profile), with one of the oral drug products, under fasted or fed conditions, followed, after a 7-day washout period, of a second single dose of oral GC4702, at the same dose as before, under the opposite condition (fed or fasting). In the food effect cohort, subjects will be randomly assigned 1:1 to the fed-fasted sequence (i.e., either fed-first or fasted-first). For the fed condition, subjects will receive a standard meal. There will be no placebo dosing or IV GC4419 dosing in the food effect cohort

Eligibility criteria: Inclusion Criteria:

1. Healthy men and women, age 18 and 50 years
2. Body Mass Index (BMI) 18 to 32 kg/m2, and weighing at least 50 kg at screening.
3. Blood pressure and heart rate within normal limits
4. Non-lactating, non-pregnant female, confirmed by urine pregnancy screening and willing to use acceptable methods of birth control, per medical and institutional practice.

Exclusion Criteria:

1. History of any chronic disease; or significant medical condition within three months, including but not limited to human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C
2. Use of any prescription or over-the-counter medication within one week prior to baseline
3. Anticipated need for any medication during the course of the study, with the exception of contraceptive and hormone replacement therapy
4. Use of any medications that at risk for causing a precipitous decrease in blood pressure, (e.g., nitrates or erectile dysfunction drugs, from 24 hours prior to screening and throughout participation in the study)
5. Use of any vitamin or mineral supplement 24 hours prior to dosing, or anticipated use of any vitamin or mineral supplement throughout the duration of the study;
6. History of substance abuse, drug addiction, or alcoholism within 3 years prior to Baseline and/or the inability to abstain from alcohol, or drug use from 48 hours prior to the administration of study drug and throughout the duration of the study as confirmed by toxicology screens during Screening and at Baseline
7. History of smoking or any use of a tobacco product within six months prior to Baseline and/or the inability to abstain from tobacco or caffeine use from 48 hours prior to the administration of study drug and throughout the duration of the study.
8. Donation of blood or blood products within 30 days prior to the Baseline
9. Subject has previously participated in this study.

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events and Laboratory Abnormalities
timeFrame: From randomization through 4 days post last dosing in Active Phase of each cohort.
Secondary outcomes:
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: Nucleus Network Limited
state: Victoria
Study officials:
affiliation: Galera Therapeutics, Inc.
name: Jon T Holmlund, MD
role: STUDY_CHAIR
affiliation: Nucleus Network
name: Jason Lickliter, MBBS, PhD, FRACP
role: PRINCIPAL_INVESTIGATOR
affiliation: Syneos Health
name: David Fuller, MD
role: STUDY_DIRECTOR
References:
citation: Squillace S, Salvemini D. Nitroxidative stress in pain and opioid-induced adverse effects: therapeutic opportunities. Pain. 2022 Feb 1;163(2):205-213. doi: 10.1097/j.pain.0000000000002347. No abstract available.